Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HANK cells
- Development stage
- Phase 2
- Lead developer
- HANK Bioengineering
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HANK (Highly Active Natural Killer) cells are a proprietary cell-based immunotherapy developed and administered by Guangzhou Fuda Cancer Hospital. The therapy involves the ex vivo expansion and activation of natural killer (NK) cells—derived from either the patient (autologous) or a donor (allogeneic)—to achieve high cell counts (approximately 10 billion) and high purity. These activated NK cells are reinfused intravenously to recognize and eliminate cancer cells as part of the innate immune response. HANK cell therapy is typically integrated into the hospital's Combined Immunotherapy for Cancer (CIC) protocol and has been specifically investigated in Phase 1/2 clinical trials for treating small metastases in colorectal cancer.
- Brand names
- HANK cells
- Other names
- Highly Active Natural Killer cellsHigh-activity natural killer cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)NKG2D (Natural killer group 2 member D receptor)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))
Beyond the preview
Go deeper on HANK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HANK cells.